CoA Therapeutics, Inc., a BridgeBio company
1 clinical trials · Sponsor
◉ Watch CoA Therapeutics, Inc., a BridgeBio company
| Record | Firm | Date |
|---|---|---|
| A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia (NCT04836494) | CoA Therapeutics, Inc., a BridgeBio company | 2021-03-25 |
Track CoA Therapeutics, Inc., a BridgeBio company automatically
Every clearance here is in the API, with alerts when new ones post.